Clinical Trials Logo

Advanced Malignant Tumors clinical trials

View clinical trials related to Advanced Malignant Tumors.

Filter by:

NCT ID: NCT05223231 Recruiting - Clinical trials for Advanced Malignant Tumors

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Start date: February 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is a phase I/II study, which is designed to evaluate the safety, tolerance, pharmacokinetic characteristics, receptor occupancy (RO), immunogenicity and effectiveness of LBL-019 monotherapy or combined with anti-PD-1 antibody in patients with advanced malignant tumors.

NCT ID: NCT05214482 Recruiting - Clinical trials for Advanced Malignant Tumors

A Study of AK112 in Advanced Malignant Tumors

Start date: January 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117(Anti-CD47 Antibody)with or without chemotherapy in advanced malignant tumors

NCT ID: NCT05110807 Recruiting - Clinical trials for Advanced Malignant Tumors

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors

Start date: January 5, 2022
Phase: Phase 1
Study type: Interventional

TQB3617 is a bromodomain and extra-terminal (BET) inhibitor that can competitively bind to bromodomains (BRDs) with Acetylated lysine(Kac) and block or partially block the role of KAc in subsequent gene transcription and regulation of chromatin structure, thereby playing an anti-tumor role.

NCT ID: NCT04980690 Recruiting - Clinical trials for Advanced Malignant Tumors

Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors

Start date: August 31, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/IIa study to evaluate the safety, tolerability and efficacy of IBC0966 for the treatment of subjects with advanced malignant tumors.

NCT ID: NCT04128085 Recruiting - Clinical trials for Advanced Malignant Tumors

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors

Start date: November 15, 2019
Phase: Phase 1
Study type: Interventional

This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), phase II recommended dose (RP2D), and maximum tolerated dose (MTD) of single and multiple oral doses of TQB3804 in patients with advanced malignant tumors.